AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will host an industry symposium on how a precision prevention approach to Parkinson’s disease may now be within reach, based on lessons from Alzheimer’s disease.
– AC Immune to host symposium highlighting Precision Prevention approach to Parkinson’s disease
– Presentation at International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626